Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.41 |
| ▸ | LPL | P06858 | 8/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180731 | 0.82 | DGAT1 (0.66) | DGAT1LIPGLPL | |
| SCHEMBL29986429 | 0.82 | DGAT1 (0.66) | DGAT1LIPGLPL | |
| SCHEMBL29197817 | 0.82 | DGAT1 (0.55) | DGAT1LIPGLPLNUDT1ALDH1A1 | |
| SCHEMBL15635069 | 0.81 | DGAT1 (0.52) | DGAT1LIPGLPLGABRPGABRD | |
| SCHEMBL30631514 | 0.81 | DGAT1 (0.52) | DGAT1LIPGLPLGABRPGABRD | |
| SCHEMBL31444224 | 0.79 | DGAT1 (0.48) | DGAT1LIPGLPLALDH1A1 | |
| SCHEMBL31333705 | 0.77 | DGAT1 (0.54) | DGAT1LIPGLPLGABRG2GABRB3 | |
| SCHEMBL23302036 | 0.77 | DGAT1 (0.47) | DGAT1LIPGLPLGABRPGABRD | |
| SCHEMBL18301360 | 0.77 | DGAT1 (0.47) | DGAT1LIPGLPLGABRPGABRD | |
| SCHEMBL29755762 | 0.77 | DGAT1 (0.47) | DGAT1LIPGLPLGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564233-B1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2023-05-03 | — | — | EP | disclosed |
| EP-4101849-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| US-20220387428-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-11229648-B2 | 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2022-01-25 | — | — | US | disclosed |
| EP-2885288-B1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20200345732-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10758533-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2020-09-01 | — | — | US | disclosed |
| EP-3564233-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| US-10195196-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2019-02-05 | — | — | US | disclosed |
| US-20170290828-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2017-10-12 | — | — | US | disclosed |
| US-9545404-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2885288-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-20140213570-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-8729263-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2014-05-20 | — | — | US | disclosed |
| US-20140051672-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2014-02-20 | — | — | US | disclosed |
| WO-2014028459-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758533-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, SF3B5 | DGAT1 4016/4885LIPG 4554/4885LPL 2609/4885 |
| US-20140213570-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | DGAT1 4016/4885LIPG 4554/4885LPL 2609/4885 |
| US-11229648-B2 | 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, SF3B5, CLN6 | DGAT1 4113/4885LIPG 4619/4885LPL 2552/4885 |
| US-20170290828-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | DGAT1 4016/4885LIPG 4554/4885LPL 2609/4885 |
| US-20140051672-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | DGAT1 4016/4885LIPG 4554/4885LPL 2609/4885 |
| US-20200345732-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | DGAT1 4016/4885LIPG 4554/4885LPL 2609/4885 |
| US-20220387428-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | DGAT1 4016/4885LIPG 4554/4885LPL 2609/4885 |
| US-10195196-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, SF3B5 | DGAT1 4016/4885LIPG 4554/4885LPL 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.